Monday 11 May 2015

• 11:00 - Roles of metabolic reprogramming in disease
  Status: This talk is in preparation - details may change
  TBA

Monday 8 June 2015

• 11:00 - The DNA Damage Response
  Dr Kyle Miller (University of Texas at Austin)
  Department of Oncology

Tuesday 23 June 2015

• 13:00 - Oxidation of nucleic acids and control mechanism of spontaneous mutagenesis and tumorigenesis in mammals
  Professor Yusaku Nakebeppu (Medical Institute of Bioregulations, Japan)
  Department of Oncology

Monday 13 July 2015

• 11:00 - Cohesin and Mediator control immunoglobulin class switch recombination
  Bernardo Reina-San-Martin (IGBMC)

Friday 24 July 2015

• 12:15 - Replication fork collapse through ATR inhibition as a cancer treatment
  Dr Eric Brown (University of Pennsylvania)
  Department of Oncology

Monday 27 July 2015

• 11:00 - From Genome Integrity to Genome Plasticity: the Yin-Yang of DNA Replication Control
  Professor Zoi Lygerou (University of Patras, Greece)
  Department of Oncology

Tuesday 1 September 2015

• 11:00 - Basic Mechanisms of Fibrosis and Epigenetic Control
  Professor Derek Mann (Newcastle University Medical School)
  Department of Oncology

Monday 7 September 2015

• 11:00 - Pluripotent stem cells to study neurodegenerative disease and treat neurological disorders
  PD Dr Philipp Koch (Institute of Reconstructive Neurobiology, Life & Brain Center, Sigmund-Freud-Str.25, )
  Department of Oncology

Wednesday 9 September 2015

• 10:00 - Study of the early radiation-induced DNA damage: a computational approach
  Professor Dr Mario Bernal (UNICAMP)
  Department of Oncology

Monday 14 September 2015

• 11:00 - Mechanisms of synergy between ionizing radiation and a therapeutic HPV vaccine
  Professor Eric Deutsch (Gustave Roussy, France)
  Department of Oncology

Monday 26 October 2015

• 11:00 - DNA replication and genome stability: novel molecular insights from a vertebrate cell free system
  Dr Vincenzo Costanzo (IFOM)
  Department of Oncology

Monday 2 November 2015

• 11:00 - Development of AZD5363, an inhibitor of AKT with activity in tumours containing mutations in the P13K-AKT pathway
  Dr Barry Davis ( AstraZeneca)
  Department of Oncology

Monday 16 November 2015

• 11:00 - Maximising anti-tumour immune activation with oncology virotherapy
  Professor Alan Melcher (University of Leeds)
  Department of Oncology